US Patent

US11253515 — Pharmaceutical compositions and dosage forms

Formulation · Assigned to Ignyta Inc · Expires 2038-07-18 · 12y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions and dosage forms of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide for treating cancer.

USPTO Abstract

Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.

Drugs covered by this patent

Patent Metadata

Patent number
US11253515
Jurisdiction
US
Classification
Formulation
Expires
2038-07-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Ignyta Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.